Apellis Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03753U1060
USD
21.75
2.36 (12.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
458.58
178.49
166.80
212.53
196.83
199.69
172.32
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
458.58
178.49
166.80
212.53
196.83
199.69
172.32
Raw Material Cost
24.87
14.07
34.81
40.86
34.01
23.55
20.65
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
11.28
11.15
11.05
11.53
12.53
9.36
6.97
Selling and Distribution Expenses
142.34
130.69
128.90
121.48
121.53
127.63
129.06
Other Expenses
5.69
5.59
7.54
6.48
7.60
6.86
7.77
Total Expenditure (Excl Depreciation)
235.40
211.78
250.12
238.69
244.11
229.13
234.41
Operating Profit (PBDIT) excl Other Income
223.2
-33.3
-83.3
-26.200000000000003
-47.300000000000004
-29.4
-62.1
Other Income
4.41
2.75
2.49
1.63
2.96
3.21
2.80
Operating Profit (PBDIT)
227.94
-30.09
-80.39
-24.09
-43.86
-25.79
-58.84
Interest
11.28
11.15
11.05
11.53
12.53
9.36
6.97
Exceptional Items
0.00
0.00
0.00
0.00
0.00
-1.95
0.00
Gross Profit (PBDT)
433.71
164.42
131.99
171.67
162.82
176.14
151.67
Depreciation
0.34
0.45
0.45
0.45
0.46
0.45
0.44
Profit Before Tax
216.32
-41.69
-91.88
-36.07
-56.85
-37.54
-66.25
Tax
0.60
0.47
0.34
0.29
0.59
0.11
0.17
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
215.72
-42.15
-92.22
-36.35
-57.45
-37.66
-66.42
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
215.72
-42.15
-92.22
-36.35
-57.45
-37.66
-66.42
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
215.72
-42.15
-92.22
-36.35
-57.45
-37.66
-66.42
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
401.17
156.31
164.22
228.54
237.12
264.33
266.68
Earnings per share (EPS)
1.66
-0.33
-0.74
-0.29
-0.46
-0.3
-0.54
Diluted Earnings per share
1.66
-0.33
-0.74
-0.29
-0.46
-0.3
-0.54
Operating Profit Margin (Excl OI)
48.67%
-18.65%
-49.96%
-12.31%
-24.02%
-14.74%
-36.03%
Gross Profit Margin
47.25%
-23.1%
-54.82%
-16.76%
-28.65%
-18.58%
-38.19%
PAT Margin
47.04%
-23.61%
-55.29%
-17.11%
-29.19%
-18.86%
-38.55%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Sep 2025 is 133.03% vs 78.26% in Sep 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is 475.78% vs 59.06% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is 577.56% vs 65.76% in Sep 2024

stock-summary

Interest

YoY Growth in quarter ended Sep 2025 is -9.60% vs 71.23% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024

Compare Quarterly Results Of Apellis Pharmaceuticals, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
458.58
390.66
67.92
17.39%
Other Operating Income
0.00
0.00
0.00
Total Operating income
458.58
390.66
67.92
17.39%
Raw Material Cost
24.87
50.96
-26.09
-51.20%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
11.28
0.00
11.28
Selling and Distribution Expenses
142.34
170.85
-28.51
-16.69%
Other Expenses
5.69
7.59
-1.90
-25.03%
Total Expenditure (Excl Depreciation)
235.40
297.68
-62.28
-20.92%
Operating Profit (PBDIT) excl Other Income
223.18
92.98
130.20
140.03%
Other Income
4.41
11.86
-7.45
-62.82%
Operating Profit (PBDIT)
227.94
112.66
115.28
102.33%
Interest
11.28
0.00
11.28
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
433.71
339.70
94.01
27.67%
Depreciation
0.34
7.82
-7.48
-95.65%
Profit Before Tax
216.32
104.84
111.48
106.33%
Tax
0.60
17.74
-17.14
-96.62%
Provisions and contingencies
0
0
0.00
Profit After Tax
215.72
87.10
128.62
147.67%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
215.72
87.10
128.62
147.67%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
215.72
87.10
128.62
147.67%
Equity Capital
0
0
0.00
Face Value
0.00
0.01
0.00
Reserves
401.17
1,624.58
-1,223.41
-75.31%
Earnings per share (EPS)
1.66
0.52
1.14
219.23%
Diluted Earnings per share
1.66
0.52
1.14
219.23%
Operating Profit Margin (Excl OI)
48.67%
23.80%
0.00
24.87%
Gross Profit Margin
47.25%
28.84%
0.00
18.41%
PAT Margin
47.04%
22.30%
0.00
24.74%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 45.86 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 156.92% vs 7.01% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 133.03% vs 78.26% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 21.57 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 611.14% vs 54.23% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 475.78% vs 59.06% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 22.35 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 781.40% vs 60.43% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 577.56% vs 65.76% in Sep 2024

Quarterly - Interest
Interest 1.13 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 0.89% vs 1.82% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is -9.60% vs 71.23% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 48.67%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024